Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avalglucosidase alfa in deteriorating non-classic Pompe disease
NL-OMON60106Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avalglucosidase alfa in Pompe disease, sponsored by Erasmus MC. Primary endpoints: Adverse events and treatment-emergent adverse events, Anti-drug antibodies and 6 more. Started Oct 2024; status: recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON60106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60106.